Nicoletta Luciano, Elisa Barone, Enrico Brunetta, Alessio D’Isanto, Maria De Santis, Angela Ceribelli, Marta Caprioli, Giacomo M. Guidelli, Daniela Renna, Carlo Selmi
{"title":"肥胖和纤维肌痛与难治性类风湿关节炎(D2T-RA)相关,与年龄和性别无关","authors":"Nicoletta Luciano, Elisa Barone, Enrico Brunetta, Alessio D’Isanto, Maria De Santis, Angela Ceribelli, Marta Caprioli, Giacomo M. Guidelli, Daniela Renna, Carlo Selmi","doi":"10.1186/s13075-024-03432-4","DOIUrl":null,"url":null,"abstract":"There is still a significant proportion of patients with rheumatoid arthritis (RA) in whom multiple therapeutic lines are ineffective. These cases are defined by the EULAR criteria as Difficult-to-Treat RA (D2T-RA) for which there is limited knowledge of predisposing factors. To identify the clinical features associated with D2T-RA in real-life practice. We retrospectively collected demographic, clinical, and serological data on 458 patients consecutively seen for RA between January 2019 and January 2023. We compared patients fulfilling the D2T-RA criteria with the remaining RA cohort using univariate comparisons and logistic regression to determine the impact of clinical features, comorbidities on outcome variable, adjusted for confounders. Seventy-one/458 (16%) patients fulfilled the 2021 EULAR criteria for D2T-RA with no significant differences for age (median 62 years interquartile range -IQR- 58- 65 vs. 62 IQR 60 – 63 in non-D2T), gender prevalence (23% in both groups) and positivity rates for rheumatoid factors (62% vs. 62% in non-D2T) and Anti-Citrullinated Protein Antibodies (ACPA) (69% vs. 61% in non-D2T). Conversely, D2T-RA cases had significant longer disease duration (median 15 years IQR 13–17 vs. 10 years IQR 9–11 in non-D2T; p < 0.0001). D2T-RA also had more erosions at baseline (24% vs. 11% in non-D2T; p < 0.0001) and higher disease activity index (CDAI) at the last follow up visit (15.7 ± 10.5 vs. 7.5 ± 8.8 in non-D2T; p < 0.0001). D2T-RA cases suffered with higher frequency of obesity (33% vs. 19% in non-D2T, p = 0.021) and fibromyalgia (25% vs. 10% in non-D2T, p < 0.0001). The multivariate analysis confirmed the correlations of D2T-RA with disease duration (Odds ratio -OR- 1.06, 95% confidence interval -CI—1.03–1.09; p < 0.0001), baseline erosions (OR 2.73, 95% CI 1.28–5.82; p = 0.009), obesity (OR 2.22, 95% CI 1.10–4.50; p = 0.026) and fibromyalgia (OR 3.91, 95% CI 1.76–8.70; p = 0.001), independent of age and gender. High disease activity, baseline erosions and disease duration are significantly associated with the D2T phenotype of RA while we confirm the importance of obesity and fibromyalgia.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"36 1","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Obesity and fibromyalgia are associated with Difficult-to-Treat Rheumatoid Arthritis (D2T-RA) independent of age and gender\",\"authors\":\"Nicoletta Luciano, Elisa Barone, Enrico Brunetta, Alessio D’Isanto, Maria De Santis, Angela Ceribelli, Marta Caprioli, Giacomo M. Guidelli, Daniela Renna, Carlo Selmi\",\"doi\":\"10.1186/s13075-024-03432-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"There is still a significant proportion of patients with rheumatoid arthritis (RA) in whom multiple therapeutic lines are ineffective. These cases are defined by the EULAR criteria as Difficult-to-Treat RA (D2T-RA) for which there is limited knowledge of predisposing factors. To identify the clinical features associated with D2T-RA in real-life practice. We retrospectively collected demographic, clinical, and serological data on 458 patients consecutively seen for RA between January 2019 and January 2023. We compared patients fulfilling the D2T-RA criteria with the remaining RA cohort using univariate comparisons and logistic regression to determine the impact of clinical features, comorbidities on outcome variable, adjusted for confounders. Seventy-one/458 (16%) patients fulfilled the 2021 EULAR criteria for D2T-RA with no significant differences for age (median 62 years interquartile range -IQR- 58- 65 vs. 62 IQR 60 – 63 in non-D2T), gender prevalence (23% in both groups) and positivity rates for rheumatoid factors (62% vs. 62% in non-D2T) and Anti-Citrullinated Protein Antibodies (ACPA) (69% vs. 61% in non-D2T). Conversely, D2T-RA cases had significant longer disease duration (median 15 years IQR 13–17 vs. 10 years IQR 9–11 in non-D2T; p < 0.0001). D2T-RA also had more erosions at baseline (24% vs. 11% in non-D2T; p < 0.0001) and higher disease activity index (CDAI) at the last follow up visit (15.7 ± 10.5 vs. 7.5 ± 8.8 in non-D2T; p < 0.0001). D2T-RA cases suffered with higher frequency of obesity (33% vs. 19% in non-D2T, p = 0.021) and fibromyalgia (25% vs. 10% in non-D2T, p < 0.0001). The multivariate analysis confirmed the correlations of D2T-RA with disease duration (Odds ratio -OR- 1.06, 95% confidence interval -CI—1.03–1.09; p < 0.0001), baseline erosions (OR 2.73, 95% CI 1.28–5.82; p = 0.009), obesity (OR 2.22, 95% CI 1.10–4.50; p = 0.026) and fibromyalgia (OR 3.91, 95% CI 1.76–8.70; p = 0.001), independent of age and gender. High disease activity, baseline erosions and disease duration are significantly associated with the D2T phenotype of RA while we confirm the importance of obesity and fibromyalgia.\",\"PeriodicalId\":8419,\"journal\":{\"name\":\"Arthritis Research & Therapy\",\"volume\":\"36 1\",\"pages\":\"\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2025-01-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Arthritis Research & Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s13075-024-03432-4\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arthritis Research & Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13075-024-03432-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
仍有相当比例的类风湿关节炎(RA)患者,其多种治疗方法无效。这些病例被EULAR标准定义为难治性RA (D2T-RA),对其易感因素的了解有限。在现实生活中识别与D2T-RA相关的临床特征。我们回顾性收集了2019年1月至2023年1月期间连续观察的458例RA患者的人口学、临床和血清学数据。我们将满足D2T-RA标准的患者与其余RA队列进行比较,采用单因素比较和逻辑回归来确定临床特征、合并症对结果变量的影响,并根据混杂因素进行调整。71 /458例(16%)患者符合2021年D2T-RA的EULAR标准,年龄(中位数为62岁,四分位数范围为-IQR- 58- 65,非d2t为62 IQR- 60 - 63)、性别患病率(两组均为23%)和类风湿因子阳性率(非d2t为62%,非d2t为62%)和抗citrullinated Protein Antibodies (ACPA)阳性率(69%,非d2t为61%)无显著差异。相反,D2T-RA病例的病程明显更长(中位15年IQR 13-17,非d2t患者为10年IQR 9-11;p < 0.0001)。D2T-RA在基线时也有更多的侵蚀(24% vs. 11%;p < 0.0001),最后一次随访时疾病活动指数(CDAI)较高(15.7±10.5 vs.非d2t组为7.5±8.8;p < 0.0001)。D2T-RA患者肥胖(33% vs.非d2t患者的19%,p = 0.021)和纤维肌痛(25% vs.非d2t患者的10%,p < 0.0001)的发生率更高。多因素分析证实D2T-RA与病程相关(优势比- or - 1.06, 95%可信区间- ci - 1.03 - 1.09;p < 0.0001),基线侵蚀(OR 2.73, 95% CI 1.28-5.82;p = 0.009),肥胖(OR 2.22, 95% CI 1.10-4.50;p = 0.026)和纤维肌痛(OR 3.91, 95% CI 1.76-8.70;P = 0.001),与年龄和性别无关。高疾病活动度、基线侵蚀和疾病持续时间与RA的D2T表型显著相关,同时我们证实肥胖和纤维肌痛的重要性。
Obesity and fibromyalgia are associated with Difficult-to-Treat Rheumatoid Arthritis (D2T-RA) independent of age and gender
There is still a significant proportion of patients with rheumatoid arthritis (RA) in whom multiple therapeutic lines are ineffective. These cases are defined by the EULAR criteria as Difficult-to-Treat RA (D2T-RA) for which there is limited knowledge of predisposing factors. To identify the clinical features associated with D2T-RA in real-life practice. We retrospectively collected demographic, clinical, and serological data on 458 patients consecutively seen for RA between January 2019 and January 2023. We compared patients fulfilling the D2T-RA criteria with the remaining RA cohort using univariate comparisons and logistic regression to determine the impact of clinical features, comorbidities on outcome variable, adjusted for confounders. Seventy-one/458 (16%) patients fulfilled the 2021 EULAR criteria for D2T-RA with no significant differences for age (median 62 years interquartile range -IQR- 58- 65 vs. 62 IQR 60 – 63 in non-D2T), gender prevalence (23% in both groups) and positivity rates for rheumatoid factors (62% vs. 62% in non-D2T) and Anti-Citrullinated Protein Antibodies (ACPA) (69% vs. 61% in non-D2T). Conversely, D2T-RA cases had significant longer disease duration (median 15 years IQR 13–17 vs. 10 years IQR 9–11 in non-D2T; p < 0.0001). D2T-RA also had more erosions at baseline (24% vs. 11% in non-D2T; p < 0.0001) and higher disease activity index (CDAI) at the last follow up visit (15.7 ± 10.5 vs. 7.5 ± 8.8 in non-D2T; p < 0.0001). D2T-RA cases suffered with higher frequency of obesity (33% vs. 19% in non-D2T, p = 0.021) and fibromyalgia (25% vs. 10% in non-D2T, p < 0.0001). The multivariate analysis confirmed the correlations of D2T-RA with disease duration (Odds ratio -OR- 1.06, 95% confidence interval -CI—1.03–1.09; p < 0.0001), baseline erosions (OR 2.73, 95% CI 1.28–5.82; p = 0.009), obesity (OR 2.22, 95% CI 1.10–4.50; p = 0.026) and fibromyalgia (OR 3.91, 95% CI 1.76–8.70; p = 0.001), independent of age and gender. High disease activity, baseline erosions and disease duration are significantly associated with the D2T phenotype of RA while we confirm the importance of obesity and fibromyalgia.
期刊介绍:
Established in 1999, Arthritis Research and Therapy is an international, open access, peer-reviewed journal, publishing original articles in the area of musculoskeletal research and therapy as well as, reviews, commentaries and reports. A major focus of the journal is on the immunologic processes leading to inflammation, damage and repair as they relate to autoimmune rheumatic and musculoskeletal conditions, and which inform the translation of this knowledge into advances in clinical care. Original basic, translational and clinical research is considered for publication along with results of early and late phase therapeutic trials, especially as they pertain to the underpinning science that informs clinical observations in interventional studies.